Search Results
Apr 10, 2026, 09:55 ET Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related DiseaseIssued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen,
More news about: USA News Group
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
and is expanding into adult indications for steroid-refractory acute graft-versus-host disease, with over 1,000 granted patents. Longeveron (NASDAQ: LGVN) published Phase 2b results in Cell Stem Cell showing that its stem cell therapy improved physical condition in patients with age-related frailty, including
More news about: Equity Insider
Mar 03, 2026, 10:02 ET Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), and Longeveron (NASDAQ: LGVN).
More news about: USA News Group